Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …

Management of neuroendocrine neoplasia represents a clinical challenge because of its
late presentation, lack of treatment options, and limitations in present imaging modalities …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

Background The lack of an accurate blood biomarker in neuroendocrine tumor (NET)
disease has hindered management. The advance of genomic medicine and the …

Owing to the heterogeneity of neuroendocrine neoplasms (NENs), the availability of reliable
circulating markers is critical for improving diagnostics, prognostic stratification, follow-up …

Over the past 5 years, a number of notable research advances have been made in the field
of neuroendocrine cancer, specifically with regard to neuroendocrine cancer of the …

Context: Early and precise delineation of therapeutic responses are key issues in
neuroendocrine neoplasm/tumor management. Imaging is currently used but exhibits …

Abstract Purpose Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated
pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic …

The complexity of the clinical management of neuroendocrine neoplasia (NEN) is
exacerbated by limitations in imaging modalities and a paucity of clinically useful …

Background/Aims: A key issue in gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) is early identification and prediction of disease progression. Clinical evaluation and …